In recent studies, altered levels of CHIT and CHI3L2 have been observed across a spectrum of neurological disorders, including MS, Alzheimer’s disease (AD), ALS, stroke, traumatic brain injury (TBI) and Creutzfeldt–Jakob disease (CJD). Here, CHI3L2 is linked to myeloid sarcoma.